Trial Profile
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease (BMTCTN1507)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Hydroxycarbamide (Primary) ; Mesna (Primary) ; Thiotepa (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2021 Planned primary completion date changed from 1 Dec 2023 to 1 Sep 2024.